Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Dobutamine
Drug ID BADD_D00697
Description A beta-1 agonist catecholamine that has cardiac stimulant action without evoking vasoconstriction or tachycardia. It is proposed as a cardiotonic after myocardial infarction or open heart surgery.
Indications and Usage For inotropic support in the short- term treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures
Marketing Status Prescription; Discontinued
ATC Code C01CA07
DrugBank ID DB00841
KEGG ID D03879
MeSH ID D004280
PubChem ID 36811
TTD Drug ID D0J7RK
NDC Product Code 51662-1330; 0409-2344; 51662-1337
Synonyms Dobutamine | Dobucor | Dobuject | Dobutamin Fresenius | Dobutamin Hexal | Dobutamin Solvay | Dobutamin-ratiopharm | Dobutamin ratiopharm | Dobutamina Inibsa | Dobutamina Rovi | Posiject | Dobutamine Hydrobromide | Hydrobromide, Dobutamine | Dobutamine Hydrochloride | Hydrochloride, Dobutamine | Dobutamine Lactobionate | Lactobionate, Dobutamine | Dobutamine Tartrate | Tartrate, Dobutamine | Dobutamine Tartrate (1:1), (S-(R*,R*))-Isomer | Dobutamine Tartrate (1:1), (R-(R*,R*))-Isomer | Dobutamine, (-)-Isomer | Dobutamine, Phosphate (1:1) Salt (+)-Isomer | Dobutrex | Lilly 81929 | Oxiken | Dobutamine Phosphate (1:1) Salt, (-)-Isomer | Dobutamine (+)-Isomer
Chemical Information
Molecular Formula C18H23NO3
CAS Registry Number 34368-04-2
SMILES CC(CCC1=CC=C(C=C1)O)NCCC2=CC(=C(C=C2)O)O
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Angina pectoris02.02.02.002; 24.04.04.002--
Atrial fibrillation02.03.03.0020.013538%
Blood pressure increased13.14.03.0050.000742%Not Available
Blood pressure systolic increased13.14.03.006--Not Available
Cardiac arrest02.03.04.0010.000145%
Cardiomyopathy02.04.01.0010.000371%Not Available
Chest pain02.02.02.011; 08.01.08.002; 22.02.08.003--Not Available
Coronary artery disease02.02.01.001; 24.04.04.0060.000371%Not Available
Death08.04.01.0010.012336%
Drug dependence19.07.02.0090.000556%Not Available
Dyspnoea02.01.03.002; 22.02.01.004--
Eosinophilic myocarditis01.02.04.007; 02.04.03.0020.000556%Not Available
Haemorrhage intracranial17.08.01.008; 24.07.04.0030.000145%
Headache17.14.01.001--
Heart rate decreased13.14.04.0010.000927%Not Available
Heart rate increased13.14.04.0020.000371%Not Available
Hypertension24.08.02.0010.001113%
Hypokalaemia14.05.03.002--
Hypotension24.06.03.002--
Myocardial infarction02.02.02.007; 24.04.04.009--
Myocardial ischaemia02.02.02.008; 24.04.04.0100.000677%Not Available
Nausea07.01.07.001--
Palpitations02.01.02.003--
Phlebitis12.02.01.002; 24.05.03.001--
Pruritus23.03.12.001--
Restrictive cardiomyopathy02.04.01.0050.000371%
Right ventricular failure02.05.03.0020.000371%Not Available
Seizure17.12.03.001--
Sinus tachycardia02.03.03.0100.000371%
Skin exfoliation23.03.07.003--Not Available
The 1th Page    1 2    Next   Last    Total 2 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene